Literature DB >> 23372042

A genome-wide association study of resistance to HIV infection in highly exposed uninfected individuals with hemophilia A.

Jérôme Lane1, Paul J McLaren, Lucy Dorrell, Kevin V Shianna, Amanda Stemke, Kimberly Pelak, Stephen Moore, Johannes Oldenburg, Maria Teresa Alvarez-Roman, Anne Angelillo-Scherrer, Francoise Boehlen, Paula H B Bolton-Maggs, Brigit Brand, Deborah Brown, Elaine Chiang, Ana Rosa Cid-Haro, Bonaventura Clotet, Peter Collins, Sara Colombo, Judith Dalmau, Patrick Fogarty, Paul Giangrande, Alessandro Gringeri, Rathi Iyer, Olga Katsarou, Christine Kempton, Philip Kuriakose, Judith Lin, Mike Makris, Marilyn Manco-Johnson, Dimitrios A Tsakiris, Javier Martinez-Picado, Evelien Mauser-Bunschoten, Anne Neff, Shinichi Oka, Lara Oyesiku, Rafael Parra, Kristiina Peter-Salonen, Jerry Powell, Michael Recht, Amy Shapiro, Kimo Stine, Katherine Talks, Amalio Telenti, Jonathan Wilde, Thynn Thynn Yee, Steven M Wolinsky, Jeremy Martinson, Shehnaz K Hussain, Jay H Bream, Lisa P Jacobson, Mary Carrington, James J Goedert, Barton F Haynes, Andrew J McMichael, David B Goldstein, Jacques Fellay.   

Abstract

Human genetic variation contributes to differences in susceptibility to HIV-1 infection. To search for novel host resistance factors, we performed a genome-wide association study (GWAS) in hemophilia patients highly exposed to potentially contaminated factor VIII infusions. Individuals with hemophilia A and a documented history of factor VIII infusions before the introduction of viral inactivation procedures (1979-1984) were recruited from 36 hemophilia treatment centers (HTCs), and their genome-wide genetic variants were compared with those from matched HIV-infected individuals. Homozygous carriers of known CCR5 resistance mutations were excluded. Single nucleotide polymorphisms (SNPs) and inferred copy number variants (CNVs) were tested using logistic regression. In addition, we performed a pathway enrichment analysis, a heritability analysis, and a search for epistatic interactions with CCR5 Δ32 heterozygosity. A total of 560 HIV-uninfected cases were recruited: 36 (6.4%) were homozygous for CCR5 Δ32 or m303. After quality control and SNP imputation, we tested 1 081 435 SNPs and 3686 CNVs for association with HIV-1 serostatus in 431 cases and 765 HIV-infected controls. No SNP or CNV reached genome-wide significance. The additional analyses did not reveal any strong genetic effect. Highly exposed, yet uninfected hemophiliacs form an ideal study group to investigate host resistance factors. Using a genome-wide approach, we did not detect any significant associations between SNPs and HIV-1 susceptibility, indicating that common genetic variants of major effect are unlikely to explain the observed resistance phenotype in this population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23372042      PMCID: PMC3613165          DOI: 10.1093/hmg/ddt033

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  38 in total

Review 1.  Securing viral safety for plasma derivatives.

Authors:  J J Morgenthaler
Journal:  Transfus Med Rev       Date:  2001-07

2.  High frequency of CCR5-delta32 homozygosity in HCV-infected, HIV-1-uninfected hemophiliacs results from resistance to HIV-1.

Authors:  Mingdong Zhang; James J Goedert; Thomas R O'Brien
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

3.  Evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives.

Authors:  J Barretina; J Blanco; A Gutiérrez; L Puig; C Altisent; T Espanol; I Caragol; B Clotet; J A Esté
Journal:  Transfusion       Date:  2000-04       Impact factor: 3.157

4.  Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Transfusion Safety Study Group.

Authors:  S L Dietrich; J W Mosley; J M Lusher; M W Hilgartner; E A Operskalski; L Habel; L M Aledort; G F Gjerset; M A Koerper; B H Lewis
Journal:  Vox Sang       Date:  1990       Impact factor: 2.144

5.  Treatment type and amount influenced human immunodeficiency virus seroprevalence of patients with congenital bleeding disorders.

Authors:  G F Gjerset; M J Clements; R B Counts; A S Halvorsen; A R Thompson
Journal:  Blood       Date:  1991-09-15       Impact factor: 22.113

6.  1986 update of HIV seroprevalence, seroconversion, AIDS incidence, and immunologic correlates of HIV infection in patients with hemophilia A and B.

Authors:  M V Ragni; A Winkelstein; L Kingsley; J A Spero; J H Lewis
Journal:  Blood       Date:  1987-09       Impact factor: 22.113

Review 7.  Viral safety of clotting factor concentrates.

Authors:  W A Fricke; M A Lamb
Journal:  Semin Thromb Hemost       Date:  1993       Impact factor: 4.180

8.  The impact of HIV on mortality rates in the complete UK haemophilia population.

Authors:  Sarah C Darby; Sau Wan Kan; Rosemary J D Spooner; Paul L F Giangrande; Christine A Lee; Michael Makris; Caroline A Sabin; Henry G Watson; Jonathan T Wilde; Mark Winter
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

9.  Immunologic and virologic status of multitransfused patients: role of type and origin of blood products. By the AIDS-Hemophilia French Study Group.

Authors: 
Journal:  Blood       Date:  1985-10       Impact factor: 22.113

10.  A diverse range of gene products are effectors of the type I interferon antiviral response.

Authors:  John W Schoggins; Sam J Wilson; Maryline Panis; Mary Y Murphy; Christopher T Jones; Paul Bieniasz; Charles M Rice
Journal:  Nature       Date:  2011-04-10       Impact factor: 49.962

View more
  23 in total

1.  APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese.

Authors:  Daisuke Sakurai; Yasumasa Iwatani; Hitoshi Ohtani; Taeko K Naruse; Hiroshi Terunuma; Wataru Sugiura; Akinori Kimura
Journal:  Immunogenetics       Date:  2015-02-27       Impact factor: 2.846

2.  Interleukin 28A.rs12980602 and interleukin 28B.rs8103142 genotypes could be protective against HCV infection among Egyptians.

Authors:  Zainab A Zakaria; Susanne Knapp; Mohamed Hashem; Hassan Zaghla; Mark Thursz; Imam Waked; Sayed Abdelwahab
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

3.  Regulatory variation in HIV-1 dependency factor ZNRD1 associates with host resistance to HIV-1 acquisition.

Authors:  Ping An; James J Goedert; Sharyne Donfield; Susan Buchbinder; Gregory D Kirk; Roger Detels; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2014-05-19       Impact factor: 5.226

4.  Testing for risk and protective trends in genetic analyses of HIV acquisition.

Authors:  Janice M Mccarthy; Patrick R Shea; David B Goldstein; Andrew S Allen
Journal:  Biostatistics       Date:  2014-09-29       Impact factor: 5.899

5.  HLA class I and KIR genes do not protect against HIV type 1 infection in highly exposed uninfected individuals with hemophilia A.

Authors:  Nicolas Vince; Arman A Bashirova; Alexandra Lied; Xiaojiang Gao; Lucy Dorrell; Paul J McLaren; Jacques Fellay; Mary Carrington
Journal:  J Infect Dis       Date:  2014-04-08       Impact factor: 5.226

6.  Interleukin gene polymorphisms and susceptibility to HIV-1 infection: a meta-analysis.

Authors:  Chrissa G Tsiara; Georgios K Nikolopoulos; Niki L Dimou; Katerina G Pantavou; Pantelis G Bagos; Benedicta Mensah; Michael Talias; Georgia G Braliou; Dimitra Paraskeva; Stefanos Bonovas; Angelos Hatzakis
Journal:  J Genet       Date:  2018-03       Impact factor: 1.166

Review 7.  Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.

Authors:  Shinichi Oka; Kazuko Ikeda; Misao Takano; Miwa Ogane; Junko Tanuma; Kunihisa Tsukada; Hiroyuki Gatanaga
Journal:  Glob Health Med       Date:  2020-02-29

Review 8.  The impact of host genetic variation on infection with HIV-1.

Authors:  Paul J McLaren; Mary Carrington
Journal:  Nat Immunol       Date:  2015-06       Impact factor: 25.606

Review 9.  Immunogenetics of HIV disease.

Authors:  Maureen P Martin; Mary Carrington
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

Review 10.  HIV-1 and human genetic variation.

Authors:  Paul J McLaren; Jacques Fellay
Journal:  Nat Rev Genet       Date:  2021-06-24       Impact factor: 53.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.